Prevalent HD patients with higher adiponectin levels had a higher risk of composite CV outcomes (adjusted HR, 1.1; 95% CI, 1.0–1.4, per each 10.0 μg/mL increase in adiponectin). Here, ADIPOQ is linked to Huntington disease.